CTLT - Catalent, Inc.
After hours:
| Previous close | 37.72 |
| Open | 37.72 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's range | 36.93 - 37.85 |
| 52-week range | 31.45 - 115.33 |
| Volume | |
| Avg. volume | 4,360,890 |
| Market cap | 6.807B |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | 16.29 |
| EPS (TTM) | 2.32 |
| Earnings date | 28 Aug 2023 - 01 Sept 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 47.25 |
ZacksCatalent (CTLT) Expands Its Facility Capabilities in Shiga
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
Motley FoolWhy Catalent Stock Could Only Inch Higher Today
Catalent (NYSE: CTLT) investors are clearly an optimistic bunch, as lately they've been taking not-so-bad-news very positively and trading up the stock. JPMorgan Chase's (NYSE: JPM) Julia Qin was the person behind the downgrade. Catalent has been a troubled company of late, and caution is clearly warranted.
Motley FoolWhy Shares of Catalent Were Up Friday
Shares of contract drug manufacturer Catalent (NYSE: CTLT) were up more than 14% Friday afternoon after the healthcare company announced updated guidance and said it was delaying its third-quarter report for a second time. It seems counterintuitive that Catalent, after downgrading guidance and saying it was not able to prepare third-quarter earnings on time, would go up in price. The company's shares had already fallen when it announced on May 8 that its earnings report and guidance would not be on May 9, as originally scheduled.
Yahoo Finance VideoStocks mixed, Foot Locker plunges, Catalent surges in morning session
Yahoo Finance markets contributor Remy Blaire breaks down the morning market action while also taking a look at shares of Foot Locker and Catalent.
- Business Wire
Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing
SOMERSET, N.J., May 19, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Company’s Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the "Form 12b-25") with the Securities and Exchange Commission (the "SEC"); the Company’s ongoing focus on finalizing its financial statements and other disclosures in its
- Business Wire
Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call
SOMERSET, N.J., May 13, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that in light of the circumstances described in the Company’s Form 12b-25 filed on May 11, 2023, with the Securities and Exchange Commission, and the Company’s ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended
Motley FoolWhy Catalent Stock Was in the Red Again Today
The out-of-favor contract drug manufacturer saw two analysts get notably less bullish on its future.
ZacksCatalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Motley FoolWhy Catalent Stock Was a Disaster Today
The struggles of contract drugmaker Catalent (NYSE: CTLT) continued on Monday, leading to a big sell-off in the company's stock. Investors were heavily discouraged by their company's latest update, and in response traded the shares down by almost 26% on the day. In its press release on the matter, Catalent said that the delay stems from its discovery of certain noncash adjustments connected with its operations in Bloomington, Indiana.
BloombergDrug Contractor Catalent Plunges After Annual Guidance Cut, Results Delayed
(Bloomberg) -- Catalent Inc. shares traded at their lowest in three years following cuts to its annual financial outlook that hurt investor confidence in the contract drug manufacturer.Most Read from BloombergPowell’s Bet Against Recession Looks Good — Minus the Credit Crunch and a DC StandoffTexas Mass Shooting’s Bloody Images Add to Fervor in Gun DebateWhy Airfares, Hotels and Cars Are Getting So Expensive for AmericansGoldman Shells Out $215 Million to End Case on Underpaying WomenMitch McCon
Motley FoolWhy Wall Street Took a Hit From These 2 NYSE Stocks
Monday was a relatively quiet day on Wall Street, with most major benchmarks seeing modest losses at midday. With key inflation and other economic data coming in the near future, investors are watching closely for signs of what the Federal Reserve might do on the interest rate and monetary policy front in the months to come. Both Catalent (NYSE: CTLT) and Tyson Foods (NYSE: TSN) were down by double-digit percentages as of midday, and both businesses face some challenges that shareholders aren't quite sure how they will solve.
- Zacks
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
- Business Wire
Catalent Delays Third Quarter Results and Conference Call and Provides Update on Fiscal 2023 Guidance
SOMERSET, N.J., May 08, 2023--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will be delaying the release of its third fiscal quarter results and investor conference call, previously scheduled for Tuesday, May 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than May 11, 2023. The Company now expects
- Business Wire
Catalent Recommends Stockholders Reject Mini-Tender Offer From TRC Capital Investment Corporation
SOMERSET, N.J., May 05, 2023--Catalent, Inc. ("Catalent") (NYSE: CTLT) has been notified of an unsolicited "mini-tender offer" by TRC Capital Investment Corporation ("TRC") to purchase up to 2,000,000 shares of Catalent’s common stock at a price of $42.95 per share in cash. TRC’s offer price is approximately 4.43% lower than the $44.94 closing price of Catalent’s common stock on April 24, 2023, the last trading day prior to the date of the mini-tender offer (April 25, 2023).
ZacksLyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Motley FoolIs It Time to Buy the S&P 500's 3 Worst-Performing April Stocks?
Although the S&P 500 mustered a 1.5% gain last month, a bunch of tickers went south ... way south. Technically speaking, failed bank First Republic is the S&P 500's biggest loser from last month. Because JPMorgan Chase will soon be taking over First Republic, though, the stock's 75% tumble isn't a potential opportunity for investors.
ZacksCatalent (CTLT) Stock Jumps 6.8%: Will It Continue to Soar?
Catalent (CTLT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ZacksWill BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Catalent Stock Tumbled by Nearly 6% on Tuesday
A warning about revenue and the abandonment of a potential suitor are recent developments that continue to hammer sentiment on the company.
ZacksEarnings Preview: Catalent (CTLT) Q3 Earnings Expected to Decline
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Catalent Stock Dove More Than 7% Today
Extending its streak of declines, Catalent (NYSE: CTLT) stock fell again on Tuesday. A pair of analysts' price target cuts were the apparent catalysts for this latest slide. On Tuesday morning, prognosticators from Barclays (NYSE: BCS) and Deutsche Bank (NYSE: DB) made downward adjustments to their Catalent targets.
ZacksCatalent (CTLT) Declines on Profit Warnings and CFO Exit
Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.
Motley FoolWhy Catalent Stock Slumped on Monday
Contract drug manufacturer Catalent (NYSE: CTLT) was surely tempted to reach for the aspirin bottle on Monday. Bloomberg reported that morning that the conglomerate Danaher (NYSE: DHR) has dropped its pursuit of Catalent. Citing "people familiar with the matter," the Bloomberg report said Danaher is no longer considering making a buyout offer despite its earlier expression of interest.
- Business Wire
Catalent Provides Business Update and Names Ricky Hopson as Interim Chief Financial Officer
SOMERSET, N.J., April 14, 2023--Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced a business update. While complete financial information and operating data for the Company’s third fiscal quarter ended March 31, 2023 are not yet finalized, the Company expects that productivity issues and higher-than-expected costs experienced at three of its facilities, including two of its lar
ZacksHere's Why You Should Retain Catalent (CTLT) Stock for Now
Catalent's (CTLT) product and service launches, and a slew of strategic deals raise optimism about the stock.